Skip to main content

Abatacept Efficacy Giant Cell Arteritis

This appears to be the year for biologic treatments in giant cell artertis (GCA).

A novel trial from Dr. Carol Langford and colleagues has reported the results of a 49 patient trial of newly-diagnosed or relapsing GCA where all patients were treated with abatacept 10 mg/kg IV on days 1, 15, 29, week 8, together with prednisone.

At week 12, those in remission underwent a double-blinded randomization to either placebo or continued monthly abatacept. The primary endpoint was duration of remission (relapse-free survival). 

Full 12 week therapy was achieved by 41 patients and underwent a blinded randomization to abatacept or placebo.  Prednisone was tapered and discontinued in all patients at week 28.

The relapse-free survival at 12 months was 48% for those receiving abatacept and 31% for those receiving placebo (p=0.049).  Remission was longer in those on abatacept (9.9 months) compared to placebo (3.9 months, p=0.023).

There were no differences in safety between the 2 arms. 

Abatacept was effective in some with GCA. Although the safety profile was encouraging, treatment success appears to be less than that seen in the GiACTA trial with tocilizumab.

 

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject